A new review published in Genes & Diseases highlights macrophage-targeted therapy as a promising frontier in cardiac regeneration and myocardial repair.

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe ...

From 2019-2023, North Carolina increased the number of life sciences business establishments by 43%. To learn more in the ...

Pancreatic cancer remains one of the most challenging tumors to treat, partly because it is often discovered at advanced ...

Researchers identified a gene that seems to help slow brain aging in women, and studied links between hormone therapy, ...

Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Johns Hopkins Medicine laboratory scientists say they have developed a potential new way to treat a variety of rare genetic ...

Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...

Researchers at the University of Iowa say the tiny tardigrade, which is found all over our planet, can protect human skin and ...

Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...

This recently published exploration into the subventricular zone (SVZ) highlights its critical role in neural regeneration, ...

One of the pioneers of CAR T-cell therapy, Dr. Brentjens spoke with Becker's about what the new facility means for cancer innovation, as well as on how leaders across the U.S. can best integrate CAR T ...